In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Cardiac contractility modulation effects on exercise capacity and quality of life - an individual patient data meta-analysis of randomised controlled trials

Session Poster session 2 Sunday 08:30 - 18:00

Speaker Andrew Coats

Event : Heart Failure 2015

  • Topic : arrhythmias and device therapy
  • Sub-topic : Device Therapy
  • Session type : Poster Session

Authors : A J S Coats (Coventry,GB), F Giallauria (Naples,IT), C Vigorito (Naples,IT), M Piepoli (Piacenza,IT)

A J S Coats1 , F Giallauria2 , C Vigorito2 , M Piepoli3 , 1University of Warwick - Coventry - United Kingdom , 2Federico II University of Naples - Naples - Italy , 3G. da Saliceto Hospital, Cardiology - Piacenza - Italy ,

European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 200

Background: Although Cardiac Contractility Modulation (CCM) has emerged as a promising device treatment for heart failure (HF), the effect of CCM on functional capacity and quality of life has not been the subject of an individual patient data meta-analysis to determine its effect on measures of functional capacity and life quality. This meta-analysis aimed at systematically reviewing the latest available randomized evidence on the effectiveness of CCM on functional capacity and quality of life indexes in patients with HF.

Methods: The Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE were searched in May 2013 to identify eligible randomized controlled trials comparing CCM with sham treatment or usual care. Primary outcomes of interest were peak oxygen consumption, 6-minute walk test distance and quality of life measured by Minnesota Living With Heart Failure Questionnaire. Mean difference and 95% confidence intervals (C.I.s) were calculated for continuous data using a fixed-effects model.

Results: Three studies enrolling 641 participants were identified and included. Pooled analysis showed that, compared to control, CCM significantly improved peak oxygen consumption (mean difference +0.71, 95%C.I. 0.20 to 1.21, mL/kg/min, p = 0.006), 6-minute walk test distance (mean difference +13.92, 95%C.I. -0.08 to 27.91, meters, p = 0.05) and quality of life measured by Minnesota Living With Heart Failure Questionnaire (mean difference -7.17, 95%C.I. -10.38 to -3.96, p < 0.0001).

Conclusions: Meta-analysis of individual patient data from randomized trials suggests that CCM has significant if somewhat modest benefits in improving measures of functional capacity and quality of life, and may, therefore, following the mixed results of NECTAR-HF, ANTHEM-HF and DEFEAT-HF, be the only electrical device option for HF patients with narrow QRS with consistent RCT evidence of benefit.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are